UnknownPhase 2NCT04843839
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops
Studying Congenital hereditary endothelial dystrophy type II
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- L.V. Prasad Eye Institute
- Principal Investigator
- Muralidhar Ramappa, MSL.V. Prasad Eye Institute
- Intervention
- Nepafenac 0.1% Oph Susp(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2020 – 2022
Study locations (1)
- L V Prasad Eye Institute, Hyderabad, Banjara Hills, India
Collaborators
Allergan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04843839 on ClinicalTrials.govOther trials for Congenital hereditary endothelial dystrophy type II
Additional recruiting or active studies for the same condition.
See all trials for Congenital hereditary endothelial dystrophy type II →